Mechanism of action of gypenosides on type 2 diabetes and non-alcoholic fatty liver disease in rats

Figure 5 Representative photographs of immunohistochemical examination (× 400 magnification). A: TNF-α; B: NF-κB. (I) normal control, (II) model, (III) gypenosides (GPs) (200 mg/kg) + HFSD, (IV) GPs (400 mg/kg) + HFSD, (V) GPs (800 mg/kg) + HFSD, (VI) Quantification of TNF-α and NF-κB stained cells. Data are expressed as mean ± SD of 12 rats. ^bP < 0.01 vs normal control; ^cP < 0.05, ^dP < 0.01 vs model.